Business
Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study
DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsSystemic DNase program
About this update from Xenetic Biosciences, Inc.
[{"type":"text","content":"DNase-based oncology platform has the potential to improve outcomes of existing therapeutic agents in multiple solid tumor indicationsSystemic DNase program initially targeting multi-billion-dollar indications including pancreatic carcinomaFRAMINGHAM, MA / ACCESSWIRE / July 7, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) (\"Xenetic\" or the \"Company\"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard-to-treat cancers, today announced it has entered into a manufacturing agreement with Catalent Pharma Solutions LLC (\"Catalent\"), which will include cGMP manufacturing for the Company's recombinant protein, Human DNase I.Catalent is the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities.\"We are pleased to be working with a preeminent contract development and manufacturing organization such as Catalent, and to have the opportunity to leverage their broad expertise and successful track record with early-stage development through commercial manufacturing. We are excited to take this step forward on the path to the clinic and look forward to investigating systemic DNase as an adjunctive therapy for locally advanced or metastatic cancers,\" commented, Jeffrey Eisenberg, Chief Executive Officer of Xenetic.\"This agreement is an important step towards long-term collaboration betweenCatalent and Xenetic,\" added Vikalp Mohan, Global Vice President, Head of Drug Substance at Catalent Biologics. \"We look forward to leveraging Catalent's proven biomanufacturing expertise at our site in Madison, Wisconsin to support the advancement of Xenetic's DNase clinical development program and accelerating their path to first-in-human studies.\"Xenetic's interventional DNase based oncology platform is aimed at improving outcomes of existing treatments, including immunotherapies. The Company exclusively licensed intellectual property for uses of DNases in cancer include systemic co-administration of DNases along with standard therapies, including chemotherapy, radiation and checkpoint inhibitors, or along with conventional chimeric antigen receptor (CAR) T therapies.The DNase platform is designed to target neutrophil extracellular traps (\"NETs\"), which are weblike str...